Sarah A. Head

Sarah A. Head

Auto-generated profile, based on publicly available information

Sarah A. Head

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Cell Reports
Verified
Journal Article
Open access
JSJeroen Strating
Jeroen Strating
LLLonneke van der Linden
Lonneke van der Linden
LALucian Albulescu
Lucian Albulescu
JBJoëlle Bigay
Joëlle Bigay
MAMinetaro Arita
Minetaro Arita
FKFrank Van Kuppeveld
Frank Van Kuppeveld
Itraconazole (ITZ) is a well-known antifungal agent that also has anticancer activity. In this study, we identify ITZ as a broad-spectrum inhibitor of enteroviruses (e.g., poliovirus, coxsackievirus, enterovirus-71, rhinovirus). We demonstrate that ITZ inhibits viral RNA replication by targeting oxysterol-binding protein (OSBP) and OSBP-related protein 4 (ORP4). Consistently, OSW-1, a specific OSBP/ORP4 antagonist, also inhibits enterovirus replication. Knockdown of OSBP inhibits virus replication, whereas overexpression of OSBP or ORP4 counteracts the antiviral effects of ITZ and OSW-1. ITZ binds OSBP and inhibits its function, i.e., shuttling of cholesterol and phosphatidylinositol-4-phosphate between membranes, thereby likely perturbing the virus-induced membrane alterations essential for viral replication organelle formation. ITZ also inhibits hepatitis C virus replication, which also relies on OSBP. Together, these data implicate OSBP/ORP4 as molecular targets of ITZ and point to an essential role of OSBP/ORP4-mediated lipid exchange in virus replication that can be targeted by antiviral drugs.

10 December 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SHSarah A. Head
Sarah A. Head
WSWei Shi
Wei Shi
LZLiang Zhao
Liang Zhao
Kirill GorshkovKirill Gorshkov
Kirill Gorshkov
KPKalyan Pasunooti
Kalyan Pasunooti
JLJun O Liu
Jun O Liu
Significance: Tumors promote angiogenesis to facilitate their growth and metastasis; thus, inhibition of angiogenesis is a promising strategy for treating cancer. During angiogenesis, endothelial cells (EC) are stimulated by proangiogenic factors to proliferate and migrate, leading to the formation of new blood vessels. Understanding the mechanisms regulating EC function therefore is essential for the development of new antiangiogenic interventions. Here, we identify a novel mechanism of EC regulation by the recently discovered angiogenesis inhibitor itraconazole, mediated by direct binding to the mitochondrial protein voltage-dependent anion channel 1 (VDAC1). VDAC1 inhibition perturbs mitochondrial ATP production, leading to activation of the AMP-activated protein kinase pathway and subsequent inhibition of mechanistic target of rapamycin, a regulator of EC proliferation. This study suggests VDAC1 may serve as a new therapeutic target for angiogenesis inhibition.

20 November 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
ZWZhihong Wang
Zhihong Wang
PLPatti A Longo
Patti A Longo
MTMary Katherine Tarrant
Mary Katherine Tarrant
KKKwangsoo Kim
Kwangsoo Kim
SHSarah Head
Sarah Head
PCPhilip A Cole
Philip A Cole
The EGFR receptor tyrosine kinase is frequently mutated in lung cancer, but the mechanism by which mutations activate kinase activity are not clear. Using purified, nearly full-length EGFR, it is now seen that mutations drive activation and resistance to inhibitors through the formation of the asymmetric kinase domain dimer. Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly activated by mutation in non–small cell lung cancer. The mechanism of this oncogenic activation is not completely understood, but in contrast to that of the wild-type EGFR, it is proposed to be independent of kinase domain dimerization. Mechanistic studies on EGFR have mainly relied on cell-based assays or isolated kinase domain measurements. Here we show, using purified, near full-length human EGFR proteins (tEGFRs), that two oncogenic mutants are fully active independently of EGF and highly resistant to the therapeutic and endogenous inhibitors cetuximab, lapatinib and MIG6. Based on the pattern of inhibition and the effects of additional asymmetric kinase dimer interface mutations, we propose that these oncogenic EGFR mutants drive and strongly depend on the formation of the asymmetric kinase dimer for activation, which has implications for drug design and cancer treatment strategies.

30 August 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
QHQing-Li He
Qing-Li He
IMIl Minn
Il Minn
QWQiaoling Wang
Qiaoling Wang
PXPeng Xu
Peng Xu
SHSarah A. Head
Sarah A. Head
JLJun O Liu
Jun O Liu

1 November 2017 in Cancer Letters
Verified
Journal Article
Closed access
JLJunfang Lyu
Junfang Lyu
EYEun Ju Yang
Eun Ju Yang
SHSarah A. Head
Sarah A. Head
NANana Ai
Nana Ai
BZBaoyuan Zhang
Baoyuan Zhang
JSJoong Sup Shim
Joong Sup Shim

22 November 2016 in ACS Chemical Biology
Verified
Journal Article
Closed access
SHSarah A. Head
Sarah A. Head
WSWei Shi
Wei Shi
EYEun Ju Yang
Eun Ju Yang
BNBenjamin A. Nacev
Benjamin A. Nacev
SHSam Y. Hong
Sam Y. Hong
JLJun O Liu
Jun O Liu